Secondary AML (sAML)
AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML).1
of AML Cases
- AML-MRC accounts for ~25% of cases,
- t-AML makes up ~4-10% of cases.3,4
which is why it’s important to begin treatment as soon as possible.10
1 Ossenkoppele G, Montesinos P. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. Crit Rev Oncol Hematol. 2019;138:6-13.
2 MDS Foundation. What is MDS? https://www.mds-foundation.org/what-is-mds/. Accessed June 2, 2020.
3 Nagel G, Weber D, Fromm E, et al. German Austrian AML Study Group (AMLSG). Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96(12):1993-2003.
4 Leone G, Mele L, Pulsoni, A, et al. The incidence of secondary leukemias. Haematologica. 1999;84(10):937-945.
5 Cogle, CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Resp. 2015;10(3):272-281.
6 Porwit A, Saft L. The AML─MDS interface─leukemic transformation in myelodysplastic syndromes. J Hematopathol. 2011;4(2):69-79.
7 Cheung E, Perissinotti AJ, Bixby DL, et al. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Ann Hematol. 2019;98(3):541-559.
8 American Cancer Society. What are myelodysplastic syndromes? https://www.cancer.org/cancer/myelodysplastic-syndrome/about/what-is-mds.html. Updated January 22, 2018. Accessed May 13, 2020.
9 National Cancer Institute. NCI dictionary of cancer terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed June 2, 2020.
10 National Cancer Institute. Adult acute myeloid leukemia treatment (PDQ®) - patient version. https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq. Updated March 6, 2020. Accessed May 13, 2020.